CLINICAL_TRIALS
trial_result
· 2021-08-10
Clinical Trial Update: Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]
Summary
Phase 2 trial of enzalutamide for relapsed or refractory mantle cell lymphoma was terminated; results posted in 2021.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of Washington | Conditions: Ann Arbor Stage I Mantle Cell Lymphoma, Ann Arbor Stage II Mantle Cell Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2021-08-10